CliffBio
biologic

Niktimvo

axatilimab-csfr

Loss of exclusivityAugust 2036projected — 12-year biologic exclusivity estimate
CompanyIncyte Corporation

Drug detail

Brand nameNiktimvo
Active ingredientaxatilimab-csfr
Strength50MG/ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalAugust 2024
Marketing statusRx

More from Incyte Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Niktimvo patent cliff — loss of exclusivity August 2036 | CliffBio